Details for New Drug Application (NDA): 062547
✉ Email this page to a colleague
NDA 062547 describes CEPHALOTHIN SODIUM, which is a drug marketed by Abbott, Abraxis Pharm, Bristol, and Baxter Hlthcare, and is included in six NDAs. Additional details are available on the CEPHALOTHIN SODIUM profile page.
The generic ingredient in CEPHALOTHIN SODIUM is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
The generic ingredient in CEPHALOTHIN SODIUM is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
Summary for 062547
| Tradename: | CEPHALOTHIN SODIUM |
| Applicant: | Abbott |
| Ingredient: | cephalothin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062547
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Sep 11, 1985 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Sep 11, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
